Clinical trials: Antiplatelet Effect
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Ischemic Stroke
Antiplatelet Effects in Stroke-Patients
Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates with increased age. Most of patients rely on analgesic medication to control the pain.
- Trial name
- NCT02148939
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myocardial Infarction
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
Percutaneous coronary intervention (PCI) with stent implantation is the preferred reperfusion strategy for treatment of acute myocardial infarction (AMI).
- Trial name
- ACCELAMI2C19 (NCT00915733)
- Testing
- cilostazol, clopidogrel (Plavix), CYP2C19
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Myocardial Infarction
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
- Trial name
- ERASE-MI (NCT00546260)
- Testing
- PRT060128 Potassium
- Where
- 31 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Stable Chronic Angina
Ticagrelor vs. Clopidogrel in Post PCI Patients
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg…
- Trial name
- NCT05858918
- Testing
- Clopidogrel, Ticagrelor
- Where
- Iran
- Volunteers
- 476 people
- Sponsor
- Shiraz University of Medical Sciences
Coronary Artery Disease
Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study
Endothelial dysfunction is an important predictor - and a determinant - of adverse clinical outcome. Endothelial function is impaired by coronary artery stenting, a stud from our group has shown that it can be improved by…
- Trial name
- EST (NCT01700322)
- Testing
- Coronary stenting, Ticagrelor, Clopidogrel
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Johannes Gutenberg University Mainz
Dietary Exposure
Effect of Tomato Soffritto Intake on Biomarkers of Cardiovascular Disease in an Overweight and Obesity
The study is a prospective, controlled, randomized two-arm longitudinal crossover trial, performed in a single-centre. Hence, the investigators designed a clinical study aimed to investigate the effects of a daily intake of…
- Trial name
- FRITOCARD (NCT06161883)
- Testing
- Soffritto
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Depression
Antiplatelet Therapies in Patients With Depression and Coronary Disease
Depression after an acute coronary syndrome (ACS) but also at any time after CAD diagnosis, is highly associated with death, and it predicts mortality more than any other risk factor, comorbidity or follow-up events, suggesting…
- Trial name
- ENHANCE (NCT05821062)
- Testing
- standard Aspirin (ASA) + clopidogrel (CLP) therapy, standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy, standard ASA therapy
- Where
- 2 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Centro Cardiologico Monzino
Myocardial Infarction
Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study
The ELECTRA pilot study is a randomized, open-label, pharmacokinetic and pharmacodynamic trial designed to evaluate the effect of ticagrelor maintenance dose reduction on platelet inhibition in stable patients who recently…
- Trial name
- NCT03251859
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- Poland
- Volunteers
- 52 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Moyamoya Disease, Moyamoya Syndrome
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease characterized by progressive stenosis or occlusion at the terminal portion of the internal carotid artery, with formation of an abnormal vascular network at…
- Conditions
- Moyamoya Disease, Moyamoya Syndrome, Aspirin, Remote Ischemic Conditioning
- Trial name
- MOUNT-EASE (NCT07762547)
- Testing
- aspirin treatment, Remote Ischemic Conditioning
- Where
- China
- Volunteers
- 724 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke
Antiplatelet Effect of Ginkgo Diterpene Lactone Meglumine Injection in Acute Ischemic Stroke
This study evaluates the addition of Ginkgo Diterpene Lactone Meglumine Injection to aspirin in the treatment of acute ischemic stroke.Half of patient will receive Ginkgo Diterpene Lactone Meglumine Injection(25mg once/day…
- Trial name
- NCT05531942
- Testing
- Ginkgo Diterpene Lactone Meglumine Injection, Acetylsalicylic acid
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Antiplatelet Effect
Bleeding Time Study With AZD6482, Clopidogrel and ASA
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
- Trial name
- NCT00853450
- Testing
- AZD6482, Clopidogrel, ASA
- Where
- Sweden
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease, Percutaneous Coronary Intervention
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, which is designed to assess the anti-platelet effect of berberine in approximately 64 patients receiving aspirin and…
- Trial name
- APLABE-PCI (NCT03378934)
- Testing
- Berberine, Standard treatment, Aspirin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking Union Medical College Hospital
Coronary Artery Disease, Elective Percutaneous Coronary Intervention
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel
The purpose of this study was to assess whether interpatient variability in the platelet response to clopidogrel is partly due to polymorphisms of the hepatic cytochrome P450 (CYP450)3A and of the clopidogrel-P2Y12 receptor genes.
- Trial name
- NCT00433784
- Testing
- Clopidogrel, Blood sampling - platelet aggregation, Blood sampling - genotyping
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal